Evaluating new diagnostic methods for lung transplant rejection
Official title: Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies
Run by University of Alberta · NCT02812290 · Data updated 2026-11-12
This study is testing a new diagnostic tool to see if it can better identify lung transplant rejection in patients who are having problems with their transplanted lungs.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | University of Alberta Academic / other |
| Locations | 11 sites (Phoenix, Arizona and 10 other locations) |
| Status | Recruiting |
| Started | May 2016 |
| Main results expected | June 2027 |
| Study ends | December 2027 |
| Registry record updated | May 28, 2026 |
| Trial ID | NCT02812290 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are lung transplant recipients who are undergoing a biopsy as determined by their healthcare provider.
✕Probably not a fit
Patients who have declined participation or are unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the effectiveness of a new diagnostic system, the Molecular Microscope® Diagnostic System (MMDx), for evaluating lung transplant biopsies in patients experiencing allograft dysfunction. It compares molecular phenotyping of transbronchial biopsies with traditional diagnostic methods to improve accuracy in diagnosing lung transplant rejection. The study will involve 300 lung transplant recipients undergoing biopsies, with a focus on refining the MMDx system for better patient outcomes. The research is being conducted at multiple institutions, including the University of Alberta and other prominent medical centers.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses of lung transplant rejection, resulting in better treatment decisions and improved patient outcomes.
How similar studies have gone: Other studies have shown success in using molecular phenotyping for kidney transplants, suggesting potential for similar advancements in lung transplantation diagnostics.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All lung transplant recipients undergoing a biopsy as determined by their surgeon or physician. Exclusion Criteria: * Patients who declined participation or unable to give informed consent.
Where it's running
-
St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT
Phoenix, Arizona, United States Recruiting -
Alberta Transplant Applied Genomics Centre, University of Alberta
Edmonton, Alberta, Canada Recruiting -
Department of Medicine, University of Alberta
Edmonton, Alberta, Canada Recruiting -
Charles University/Hospital Motol
Prague, Czechia Recruiting -
University of Maryland School of Medicine
Baltimore, Maryland, United States Completed -
Division of Pulmonary and Critical Care, Washington University School of Medicine
St Louis, Missouri, United States Completed
Show 5 more locations
-
University of Texas at San Antonio
San Antonio, Texas, United States Completed -
The Alfred Hospital, Monash University
Melbourne, Australia Completed -
Department of Thoracic Surgery, Medical University of Vienna
Vienna, Austria Completed -
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada Completed -
Thoracic Surgery Transplant Clinic
Szczecin, Poland Completed
Study contacts
- Principal investigator: Philip F Halloran, MD, PhD — Faculty of Medicine and Dentistry, University of Alberta
- Study coordinator: Konrad S Famulski, PhD
- Email: konrad@ualberta.ca
- Phone: 1 780 492 1725
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hyperpolarized xenon-129 MRI signatures to detect and manage acute cellular rejection after lung transplant
We will see if hyperpolarized xenon-129 MRI can detect early acute cellular rejection in recent lung transplant recipients and guide targeted bronchoscopic sampling.
-
Comparing biopsy methods for lung transplant rejection diagnosis
This study tests which of two methods for taking lung tissue samples works better for diagnosing rejection in lung transplant patients.
-
Research on improving outcomes for lung transplant donors and recipients
This study is trying to see how different donor and medical practices affect the health of lung transplant patients and donors, while also looking for blood markers that might predict complications after the surgery.
-
Evaluating extracorporeal photopheresis for subclinical lung transplant rejection
This study is testing if a light-based treatment called extracorporeal photopheresis can help lung transplant patients who have early signs of rejection feel better and improve their health.
-
Testing the effectiveness of belumosudil for treating lung transplant rejection
This study is testing if belumosudil can help improve lung function in adults who have had a lung transplant and are experiencing ongoing issues with their new lungs.
-
Identifying biomarkers for lung transplant dysfunction
This study is trying to find specific markers in the body that can help doctors understand and manage problems after lung transplants for patients at Foch Hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.